Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC

This study is a single arm, multi-center, prospective clinical trial. The purpose of this study is to evaluate the efficacy and safety of liposomal irinotecan combined with anlotinib hydrochloride for relapsed small-cell lung cancer, who have progressed on or less than 6 month after platinum-based first-line therapy.

Trial Details

NCT ID
NCT06258642
Phase
NA
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Irinotecan Liposome
  • Anlotinib
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • 1\) Aged ≥18 and ≤75 years old;
  • 2\) Histologically or cytologically confirmed small cell lung cancer;
  • 3\) At least one measurable lesion according to the Response Evaluation Criteria in Solid Tumours (RECIST) 1.1;
  • 4\) Radiologically confirmed recurrence or progression within 6months after platinum-based, first-line chemotherapy or chemoradiation therapy;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →